Roth Capital Reiterates Buy on Annovis Bio, Lowers Price Target to $3

Benzinga · 2d ago
Roth Capital analyst Boobalan Pachaiyappan reiterates Annovis Bio (NYSE:ANVS) with a Buy and lowers the price target from $7 to $3.